AZD1419 is a second-generation TLR-9 agonist for asthma.
The cost of development will be fully funded by AstraZeneca, and Dynavax will receive payment of $2.6m to begin the studies as per the collaboration.
Preclinical studies have suggested that AZD1419 is capable of producing long lasting disease-modifying effects in a mouse model of atopic asthma.
Under the terms of the amended 2006 research collaboration and license agreement, AstraZeneca will provide around $20m in payments to Dynavax to cover the cost of clinical development activities through Phase 2a.